Something Old, Something New: What is a 505(b)2?
We explore the 505(b)2 pathway for expedited approval of previously-approved active drug ingredients with new formulations.
The FDA Could Approve Almost Any Drug (But It Won’t Approve That)
We discuss the role of the FDA in the drug approval process and their recent approval of the controversial Alzheimer’s drug, Aduhelm.
Three Drug Ideas that Deserve Redemption
We discuss three life science ideas that struggled on the market, but whose potential impact warrant a second look.
Good Ideas Gone Bad: The (Old & New) Worst Drug Launch In History
We discuss how approved drugs can fail on the market through a case examination of Exubera® and Aduhelm®.
Tailoring Antibodies to Suit Emerging Diseases with Ichor Biologics
We explore how Ichor Biologics is leveraging its next-generation platform to harness and improve on antibody-based therapeutics.
Shedding Senescent Cells with Deciduous Therapeutics
Our Startup Showcase examines a cutting-edge anti-aging pharma company & advice from a serial entrepreneur.
Pfizer: Erecting a New Brand Identity
We examine the aftermath and cost of Pfizer’s major rebranding effort – and discuss where the pharmaceutical giant intends to go from here.